Form 4: Beta Bionics Executive Acquires Stock Options

Mike Mensinger, Chief Product Officer of Beta Bionics, acquired stock options for 110,278 shares of Class B Common Stock on January 29, 2025.

Summary

• Mike Mensinger, the Chief Product Officer of Beta Bionics, acquired stock options on January 29, 2025.
• The options are for 110,278 shares of Class B Common Stock.
• The exercise price of the options is $17.
• The options vest monthly over a 48-month period starting January 29, 2025.
• The options expire on January 28, 2035.
• Prior to the IPO, each share of Class B Common Stock subject to the option was converted into an equal number of shares of Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a key executive aligns their interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in publicly traded companies, particularly in the tech and biotech sectors.
• The vesting schedule of 48 months is a standard practice to incentivize long-term commitment.
• The number of shares granted would need to be compared to similar companies and executive roles to determine if it is within industry norms.

Stakeholder Impact

• The stock option grant could incentivize the Chief Product Officer to improve company performance, benefiting shareholders.

Key Dates